Re: AAV8-VRC07: dal "Macaco di Miami" al trial su esseri umani
Inviato: venerdì 19 marzo 2021, 16:11
dal 2007 informazione scientifica e community, HIV e AIDS INFO e aiuto sulla sieropositività: discutiamo di HIV e AIDS, problemi della sieropositività, farmaci e ricerca scientifica.
https://hivforum.info/forum/
[...]
The phase I clinical trial enrolled eight adults with HIV who were on stable antiretroviral therapy for at least three months. Investigators found that intramuscular injection of AAV8-VRC07 was safe and well tolerated. All eight individuals produced measurable amounts of VRC07 in the blood, with maximal VRC07 concentrations in three individuals. In six individuals, these amounts remained stable and near maximal concentration for up to three years of follow-up. (The trial is ongoing, and some participants have not been followed as long as others.) Three of the eight participants showed signs of an anti-drug antibody response directed against a portion of VRC07, and this response appeared to decrease the production of VRC07 in two of the participants. [sempre il solito problema con questi bNAbs ...]
“This work represents the first successful AAV-based production of a monoclonal antibody of any kind in people,” says co-author Alejandro B. Balazs, PhD, who created the vector used in the trial and is a principal investigator at the Ragon Institute of MGH, MIT and Harvard, where his laboratory is continuing to develop this technology. “It’s also the first time we’ve had an approach capable of yielding broadly neutralizing antibodies against HIV in humans,” he says.
Balazs notes that the results have wide-ranging clinical implications for potentially preventing or treating HIV and other infections. “The findings prove that the platform we designed is capable of producing long-lived expression of an antibody from a single injection. Given our ability to encode any desired antibody into these vectors, we may be able to produce effective preventive treatments against a wide range of infectious diseases from malaria to COVID-19,” he says. “This technology also has the potential to be applied to the delivery of other biologic drugs to treat a wide range of conditions from autoimmunity to cancer.”
[...]